-
Uveitis Treatment Market Size to Reach USD 4.69 Billion by 2032, Driven by Advancements in Biologics and Rising Prevalence of Autoimmune Disorders – SNS Insider
19 Jun 2025 13:51 GMT
… Johnson & Johnson – Simponi (golimumab), Remicade (infliximab)
… and other medications are often more … presence of key pharmaceutical and biotechnology companies. High … Trial Trends and Drug Development Pipeline
6. Competitive Landscape
7. Uveitis Treatment …
-
How to opt for potentially more affordable medications when treating some autoimmune or autoinflammatory diseases
05 Jun 2025 16:18 GMT
… any vaccines.
Also tell your doctor about all the medicines … pegol), or SIMPONI® (golimumab). Tell your doctor if you have … the US by AbbVie Biotechnology Ltd; Organon is … Biologics: More Treatment Choices. US Food and Drug Administration; Updated …
-
Record-breaking FDA biosimilar approvals to create opportunities for drug developers, manufacturers, GlobalData finds
20 May 2025 15:44 GMT
… Johnson & Johnson’s Simponi. Even more biologics—18—will … in clinical supply chains, major pharmaceutical companies' intentions to … the type of drug and timeframe for trial start-up—as … and specialized requirements for trials and manufacturing due to …
-
FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara
07 May 2025 20:11 GMT
… of ustekinumab, including treatment of psoriatic arthritis … specialty high-cost medications.
“Interchangeability of … FDA, and they include AVT05, a proposed biosimilar for golimumab (Simponi; Simponi … Ustekinumab-aekn Receives FDA Approval. Drug Topics. April …
-
Teva and Alvotech Gain FDA Interchangeability for SELARSDI Biosimilar to Stelara
06 May 2025 18:42 GMT
… S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech … U.S. Food and Drug Administration (FDA) has approved SELARSDI™ … product, including the treatment of adults and pediatric … FDA: AVT05, a proposed biosimilar for Simponi (golimumab) and Simponi …
-
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 11:49 GMT
… Biotechnology Ltd. Eylea® is a registered trademark of Regeneron Pharmaceuticals … ustekinumab in clinical trials. The safety … vaccines. Avoid administering BCG vaccines during treatment … 2025.
Simponi® (golimumab) prescribing information. FDA product label …
-
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 11:00 GMT
… Biotechnology Ltd. Eylea® is a registered trademark of Regeneron Pharmaceuticals … ustekinumab in clinical trials. The safety … vaccines. Avoid administering BCG vaccines during treatment … 2025.
Simponi® (golimumab) prescribing information. FDA product label …
-
FDA approves Selarsdi injection as interchangeable with Stelara
06 May 2025 10:35 GMT
… Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA … correspond with Stelara, including the treatment for both adult and pediatric … : a proposed biosimilar for Simponi (golimumab) and Simponi Aria (golimumab), AVT05, and …
-
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
05 May 2025 15:59 GMT
… Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. … product, including the treatment of adults and pediatric … Simponi (golimumab) and Simponi Aria (golimumab).
AVT06, a proposed biosimilar for Regeneron Pharmaceuticals …
-
J&J secures FDA OK for immune drug touted as future blockbuster
30 Apr 2025 16:24 GMT
… of its top-selling medicines.
The drug, which J& … receptors. In testing, treatment improved daily function versus … its original developer, Momenta Pharmaceuticals, in 2020. Since then … blockbusters like Stelara and Simponi. The company forecasts sales …
About
© 1995-2025